Novel therapy for type 1 diabetes: Autologous hematopoietic stem cell transplantation |
| |
| Authors: | Lirong Li Weiqiong Gu Dalong Zhu |
| |
| Institution: | 1. Division of Endocrinology, The Affiliated Drum Tower Hospital of Nanjing University, , Nanjing, China;2. Department of Endocrinology and Metabolism, Ruijin Hospital Affiliated to Shanghai Jiao‐Tong University School of Medicine, , Shanghai, China |
| |
| Abstract: | Type 1 diabetes is characterized pathologically by autoimmune insulitis‐related islet β‐cell destruction. Although intensive insulin therapy for patients with type 1 diabetes can correct hyperglycemia, this therapy does not prevent all diabetes‐related complications. Recent studies have shown that autologous hematopoietic stem cell transplantation (HSCT) is a promising new approach for the treatment of type 1 diabetes by reconstitution of immunotolerance and preservation of islet β‐cell function. Herein we discuss the therapeutic efficacy and potential mechanisms underlying the action of HSCT and other perspectives in the clinical management of type 1 diabetes. |
| |
| Keywords: | autologous hematopoietic stem cells transplantation type 1 diabetes |
|
|
